Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
05/2012
05/10/2012WO2012059556A1 Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
05/10/2012WO2012059513A1 Mmp8 inactivating antigen binding proteins
05/10/2012WO2012059495A1 Optimized method for antibody capturing by mixed mode chromatography
05/10/2012WO2012059308A1 Single unit ion exchange chromatography antibody purification
05/10/2012WO2012059224A1 Immunotherapy against erbb-3 receptor
05/10/2012WO2012058768A1 Stable heterodimeric antibody design with mutations in the fc domain
05/10/2012WO2012036392A3 Human anti-epidermal growth factor receptor fab antibody and a pharmaceutical composition for treating tumours comprising the same
05/10/2012WO2012027570A3 Dual variable domain immunoglobulins and uses thereof
05/10/2012WO2012026309A9 Creation of anti-pad4 antibody pharmaceutical
05/10/2012WO2012018767A3 Antibodies directed against il-17
05/10/2012WO2012009577A3 Monoclonal antibodies against pcbp-1 antigens, and uses therefor
05/10/2012WO2011160119A3 Anti-gd2 antibodies
05/10/2012WO2011139854A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
05/10/2012WO2011139853A3 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
05/10/2012WO2010069532A8 Antibodies against human angiopoietin 2
05/10/2012US20120117670 Humanized axl antibodies
05/10/2012US20120117669 Human antibodies derived from immunized xenomice
05/10/2012US20120116060 Blockers of NMDA Receptor for the Treatment of Sickle Cell Anemia
05/10/2012US20120116059 Treatment For M Treatment For Multiple Sclerosis
05/10/2012US20120116058 URA5 Gene and Methods for Stable Genetic Integration in Yeast
05/10/2012US20120116057 Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
05/10/2012US20120116054 Concentrated protein lyophilates, methods, and uses
05/10/2012US20120115830 Assay methods for the determination of fkbpl expression level in the context of breast cancer
05/10/2012US20120115775 Mutant tat proteins and uses thereof
05/10/2012US20120115741 Reagents For The Atherosclerotic Coronary Plaque And Uses Thereof
05/10/2012US20120115247 Drug monitoring assay
05/10/2012US20120115244 Materials and methods for immunoassay of pterins
05/10/2012US20120115233 Leafhopper Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof
05/10/2012US20120115221 Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
05/10/2012US20120115169 Hydroxycholesterol immunoassay
05/10/2012US20120115168 Bioassay and peptides for use therein
05/10/2012US20120115164 Mammalian cytokines; related reagents
05/10/2012US20120115162 Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
05/10/2012US20120115161 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
05/10/2012US20120115153 Marker for prognosis of liver cancer
05/10/2012US20120115151 Method for testing a subject thought to be predisposed to having metastatic cancer using delta133p53beta
05/10/2012US20120115136 Pna diagnostic use
05/10/2012US20120115134 Methods for diagnosis and prognosis of cancer
05/10/2012US20120114742 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof
05/10/2012US20120114708 Integrin heterodimer and an alpha subunit thereof
05/10/2012US20120114704 Compounds, compositions and methods of treating cancer and fibrotic diseases
05/10/2012US20120114684 Compounds and methods for treatment and diagnosis of chlamydial infection
05/10/2012US20120114679 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/10/2012US20120114674 Molecular Antigen Array
05/10/2012US20120114673 Compositions and methods for the diagnosis and treatment of tumor
05/10/2012US20120114672 Antibodies Specific to Cadherin-17
05/10/2012US20120114671 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
05/10/2012US20120114667 TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
05/10/2012US20120114666 Neurological autoimmune disorders
05/10/2012US20120114665 Human antibodies to human rankl
05/10/2012US20120114664 Antibodies against h5n1 strains of influenza a virus
05/10/2012US20120114662 Human monoclonal antibodies against bacillus anthracis protective antigen
05/10/2012US20120114660 Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family
05/10/2012US20120114659 Antibodies for Guanylyl Cyclase Receptors
05/10/2012US20120114657 Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
05/10/2012US20120114656 Human Monoclonal Antibodies Protective Against Bubonic Plague
05/10/2012US20120114654 Human antibodies to human tnf-like ligand 1a (tl1a)
05/10/2012US20120114652 Anti-pai-1 antibodies and methods of use thereof
05/10/2012US20120114651 Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
05/10/2012US20120114650 Single chain antibodies against beta-amyloid peptide
05/10/2012US20120114647 anti-serum album single variable domains
05/10/2012US20120114644 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
05/10/2012US20120114639 Compositions and methods for inhibiting viral and/or bacterial infections
05/10/2012US20120114603 Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities
05/10/2012US20120114575 Methods for inhibiting cutaneous inflammation and hyperpigmentation
05/10/2012US20120114560 Abeta binding molecules
05/10/2012US20120114558 Aptamer-mediated drug release
05/10/2012US20120114556 Immunotherapy of autoimmune disorders using antibodies which target b-cells
05/10/2012CA2816950A1 Anti-il-23 antibodies
05/10/2012CA2816919A1 C-met antibody combinations
05/10/2012CA2816913A1 Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
05/10/2012CA2816912A1 Mmp8 inactivating antigen binding proteins
05/10/2012CA2816803A1 Dual variable domain immunoglobulins and uses thereof
05/10/2012CA2816796A1 Preparation of neutralizing antibody to human herpesvirus 6 glycoprotein q1 and analysis thereof
05/10/2012CA2816745A1 Anti c-met antibodies
05/10/2012CA2816681A1 Cytotoxic agents comprising new ansamitocin derivatives
05/10/2012CA2816520A1 Anti-her3 antibodies and compositions
05/10/2012CA2816519A1 Pan-her antibody composition
05/10/2012CA2815967A1 Anti-diabetic compounds
05/10/2012CA2815282A1 Optimized method for antibody capturing by mixed mode chromatography
05/10/2012CA2815266A1 Stable heterodimeric antibody design with mutations in the fc domain
05/10/2012CA2814781A1 Single unit ion exchange chromatography antibody purification
05/10/2012CA2813849A1 Methods of treating rheumatoid arthritis using il-17 antagonists
05/10/2012CA2813411A1 Engineered polypeptide conjugates and methods for making thereof using transglutaminase
05/09/2012EP2450710A2 Cancer biomarkers and methods of use thereof
05/09/2012EP2450382A1 Immunogenic peptide
05/09/2012EP2450381A1 Anti-RHD monoclonal antibodies
05/09/2012EP2450380A1 Anti-CD16 Binding Molecules
05/09/2012EP2450379A1 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450378A1 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450377A1 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450376A2 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450375A1 Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
05/09/2012EP2450056A1 Prevention and treatment of synucleinopathic and amyloidogenic disease
05/09/2012EP2450053A1 Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
05/09/2012EP2450050A1 IL-17A/F heterodimeric polypeptides and therapeutic uses thereof
05/09/2012EP2449127A2 Polypeptides and method of treatment
05/09/2012EP2449126A1 Novel antibodies and their uses in therapeutic and diagnostic methods
05/09/2012EP2449101A1 Neurotoxins exhibiting shortened biological activity
05/09/2012EP2449094A1 Methods of producing humanized non-human mammals
1 ... 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 ... 1494